A Case of Cutaneous Plasmacytoma Treated with Bortezomib and Radiotherapy.
- Author:
Ki Heon JEONG
1
;
Hwi Joong YOON
;
Mu Hyoung LEE
Author Information
1. Department of Dermatology, School of Medicine, Kyunghee University, Seoul, Korea. mhlee@khmc.or.kr
- Publication Type:Case Report
- Keywords:
Bortezomib;
Multiple myeloma;
Plasmacytoma;
Radiotherapy
- MeSH:
Boronic Acids;
Hematologic Neoplasms;
Humans;
Immunoglobulins;
Multiple Myeloma;
Plasma Cells;
Plasmacytoma;
Proteasome Inhibitors;
Pyrazines;
Bortezomib
- From:Korean Journal of Dermatology
2009;47(4):483-486
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Multiple myeloma is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells that produce monoclonal immunoglobulins. Cutaneous involvement is very uncommon in patients with multiple myeloma. It usually appears late in the course of the disease. Bortezomib is a potent proteasome inhibitor, recently introduced in the treatment of multiple myeloma. It has proven to be safe and effective in the treatment of refractory or relapsed multiple myeloma. In this study, we show the high efficacy of a concurrent therapeutic approach with bortezomib and radiation in a patient with a cutaneous plasmacytoma.
